Blog · Evidence, in plain language

A new ADHD medicine, and what approved actually means.

Patients in medication visits have started asking about a name they saw in headlines and short videos: Simtriyo, a new medicine for attention-deficit/hyperactivity disorder, or ADHD. The approval is real, and so is the second regulator step that followed it this fall. This post explains what kind of medicine it is, what the approval studies showed, and which parts of the story the headlines leave out.

By Karel Winner, DNP, PMHNP-BC · Published November 10, 2026

Why this name is suddenly everywhere

On July 24, 2026, the U.S. Food and Drug Administration approved a new drug application for Simtriyo, the brand name for centanafadine, for the treatment of ADHD in adults and in patients aged 6 years and older who weigh at least 20 kg. New ADHD approvals are rare enough to make news, and this one arrived with a second act: because the FDA treats the medicine as a stimulant with abuse potential, it could not be marketed until the Drug Enforcement Administration assigned it a controlled substance schedule. That step landed on October 30, 2026, when the DEA placed centanafadine in Schedule III, effective the same day. Patients have reasonably read the two headlines as one event. They are two separate decisions, by two separate agencies, and the difference matters for what a patient can actually expect.

What kind of medicine it is

The FDA label describes centanafadine in two ways at once. It is a norepinephrine-dopamine-serotonin reuptake inhibitor, which means it blocks the reabsorption of three chemical messengers involved in attention and alertness. Most older ADHD medicines act on two of those messengers at most, and the serotonin part is what makes this class new for ADHD. The label also calls it, in plain terms, a central nervous system stimulant. That second description corrects a common misunderstanding in early coverage, which grouped it with the non-stimulant ADHD medicines. By its own label it is a stimulant, it carries the stimulant warning set, and since October 30 it sits in Schedule III of the Controlled Substances Act, the category for medicines with an accepted medical use and a lower abuse potential than Schedule I or II substances, where abuse may still lead to dependence. A new mechanism is a genuine addition to the options. It is not, by itself, evidence that the medicine works better than the ones already in use.

What the approval studies found

Approval rests on four short-term studies described in section 14 of the prescribing information. All four were randomized, double-blind, and placebo-controlled, and each lasted six weeks. Two enrolled younger patients: 480 children aged 6 to 12, and 459 adolescents aged 13 to 17, with symptoms rated on the ADHD Rating Scale-5. Two enrolled adults: 466 and 440 patients aged 18 to 55, rated on the Adult ADHD Investigator Symptom Rating Scale, and those adult studies used a different formulation of centanafadine than the capsule that was approved. Across the four studies, 1,845 people were randomized. In each study, symptoms improved more on the medicine than on placebo by a statistically significant margin. Kept to scale, the extra improvement over placebo ranged from 2.7 to 5.6 points on the rating scales used. The placebo groups improved a good deal as well, which is the usual pattern in ADHD trials: structure, regular visits, and expectation do part of the work in every arm.

What the studies did not test

Three limits belong next to any headline about this approval. First, no study compared centanafadine with another ADHD medicine. Every comparison was against placebo, so the evidence cannot say whether it helps more, less, or about the same as methylphenidate, amphetamine products, or the existing non-stimulants. Anyone claiming it is stronger than a medicine you already take is claiming something the trials never measured. Second, the studies lasted six weeks. They say nothing direct about benefits or harms over the years-long periods for which ADHD medicines are usually taken. Third, the adult evidence comes from a different formulation, which the label expects to perform the same way, and that expectation is a regulatory judgment rather than a separate adult trial of the approved capsule. None of this makes the approval unsound. It makes the honest claim a narrow one: a new stimulant class beat placebo over six weeks, by a modest margin, in the groups studied.

The safety warnings, in plain language

The label opens with a boxed warning, the strongest warning the FDA uses, in two parts. The first reports that in a six-week study, suicidal thoughts and behaviors were reported at higher rates in treated children aged 6 to 12 than in children given placebo, and it directs close monitoring of all pediatric patients, especially in the first months. The second warns about abuse, misuse, and addiction: stimulant misuse can lead to a substance use disorder and, at high levels or by unapproved routes, to overdose and death. The label tells prescribers to assess that risk before starting and to keep reassessing it. For adults, the most common adverse reactions in the trials, each reported by at least 5 percent of treated patients and more often than with placebo, were headache, decreased appetite, insomnia, nausea, dry mouth, and diarrhea. The warnings section also covers ground familiar from other stimulants: blood pressure and heart rate can rise, serious cardiac disease is a reason to avoid use, new psychotic or manic symptoms can appear, and tics can emerge or worsen. One warning is specific to this medicine's serotonin activity: combined with other serotonergic medicines, it may cause serotonin syndrome, a potentially serious reaction. That matters in real medication lists, because many adults with ADHD also take an antidepressant.

Approved, scheduled, and still not a promise about your pharmacy

The DEA rule of October 30, 2026 is an interim final rule. It is in force now, and the DEA is accepting public comments on it until November 30, 2026, after which a final rule follows. An updated prescribing information document dated October 2026 now prints the Schedule III marking where the July label had left the schedule blank. What neither regulator source does is announce a date on which pharmacies will stock the medicine. In July, the manufacturer said availability would follow scheduling later this year, and a company forecast is not a regulator guarantee. So the accurate status is this: approved in July, scheduled in October, and with real-world availability, price, and insurance coverage still to be confirmed pharmacy by pharmacy. If you are stable on a current medicine, nothing about this timeline requires a decision today.

What this means at a medication visit

The useful question is not whether the new medicine is exciting. It is whether your current treatment is leaving a specific problem unsolved: symptoms that persist despite a fair trial, side effects you cannot live with, or a medicine whose timing does not fit your day. A new option matters most for patients in that position, and far less for patients whose treatment already works. If you want to raise it, bring the specifics a prescriber needs: what you take now and how it is actually working, every other medicine on your list including antidepressants, your blood pressure history, any personal or family history of substance misuse, tics, mania, or heart disease, because the label's screening list covers exactly those points. Expect the same careful order as with any stimulant change: one change at a time, a defined trial period, and a clear statement of what improvement would look like and what side effect would end the trial.

Sources

This post is based on the regulator sources below. Every number in it comes from the FDA prescribing information or the Federal Register rule.

U.S. Food and Drug Administration prescribing information for Simtriyo (centanafadine), NDA 218145, revised October 2026: the approved indication, the boxed warnings, the warnings and precautions, the most common adverse reactions, and the four clinical studies in section 14. FDA prescribing information.

U.S. Food and Drug Administration approval letter for NDA 218145, July 24, 2026: the application is approved for the treatment of attention-deficit/hyperactivity disorder, and marketing was tied to completion of controlled substance scheduling. FDA approval letter.

Drug Enforcement Administration, Schedules of Controlled Substances: Placement of Centanafadine in Schedule III, interim final rule, Federal Register volume 91, page 68470, October 30, 2026, Docket No. DEA-1743: the rule is effective October 30, 2026, and comments are due November 30, 2026. DEA interim final rule in the Federal Register.

Please read this part

Nothing here is medical advice, and reading it does not create a treatment relationship. The studies described below lasted six weeks and compared this medicine with a sugar pill, not with the ADHD medicine you may already take. If your current treatment is working, a headline about a new approval is not a reason to change it on your own. Bring the question to a medication visit, where your history, your other medicines, and your heart health can be weighed together.

If you are having thoughts of harming yourself, help is available now: call or text 988, text HOME to 741741 for Crisis Text Line, or call the NAMI Helpline at 1-800-950-6264. This practice is not an emergency service. If someone is in immediate danger, call 911. The crisis page lists more options.